Sumtra Holdings

Sumitovant Biopharma is a technology-driven biopharmaceutical company and a wholly-owned subsidiary of Sumitomo Pharma. The company was formed following a multi-billion dollar strategic alliance between Sumitomo Dainippon Pharma and Roivant Sciences, which involved the acquisition of several 'Vant' companies. Sumitovant oversees a diverse portfolio of subsidiaries, including Myovant, Urovant, Enzyvant, Altavant, and Spirovant, focusing on accelerating the development and commercialization of innovative therapies. Their pipeline spans multiple therapeutic areas such as oncology, urology, women's health, and rare diseases, supported by advanced data science and digital technology platforms.